Latest Breaking News On - Pharmaceutical systems - Page 8 : comparemela.com

Becton Dickinson & Co. (BDX) Q2 2021 Earnings Call Transcript

Operator Hello, and welcome to BD s Second Fiscal Quarter 2021 Earnings Call. At the request of BD, today s call is being recorded. It will be available for replay through May 13, 2021 on the Investors page of the bd.com website or by phone at (855) 859-2056 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 6334356. I would like to inform all parties that your lines have been placed in a listen-only mode until the question-and-answer segment. Beginning today s call is Ms. Kristen Stewart, Senior Vice President of Strategy and Investor Relations. Ms. Stewart, you may begin. Kristen M. Stewart

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance - Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. - BD s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. - BD s core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up 15.4%), and Biosciences (up 16.3%) on a reported basis. - Second fiscal quarter GAAP diluted earnings per share (EPS) increased 77.4% year-over-year to $0.94. - Adjusted EPS increased 25.1% year-over-year to $3.19. - BD is reaffirming its fiscal 2021 revenue growth and adjusted EPS guidance. News provided by Share this article

BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance

BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance - First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. - BD s COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million. - First fiscal quarter GAAP diluted earnings per share (EPS) increased 285% year-over-year to $3.35. - Adjusted EPS increased 71.7% year-over-year to $4.55. - BD is updating its fiscal 2021 guidance, including raising its fiscal 2021 adjusted EPS guidance to $12.75-$12.85. News provided by Share this article Share this article FRANKLIN LAKES, N.J., Feb. 4, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31, 2020. This represents

Global Optical Liquid Level Sensors Market 2020 Industry Insights, Top Trends, Drivers, Growth and Forecast to 2025

Global Optical Liquid Level Switches Market 2020 Industry Statistics on Key Trends, Growth and Opportunities to 2025